Lower phenytoin serum levels in persons switched from brand to generic phenytoin
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
After generic phenytoin (PHT) was marketed, the authors identified eight adult patients (ages 34 to 49) whose seizures increased enough to require intervention after switching to generic PHT. The mean total PHT concentration on brand (before generic) was 17.7 ± 5.3 mg/L, decreased to 12.5 ± 2.7 mg/L with generic, and increased to 17.8 ± 3.9 mg/L after brand was re-introduced. Brand and generic PHT do not yield equivalent concentrations in some patients and substitution should not be permitted without physician notification.
- Received January 21, 2004.
- Accepted June 17, 2004.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
- Reply to Jefferys, Sherry, Rackley, and Stetz
- Ilo Leppik, Director of Research, MINCEP Epilepsy Care, Suite 200, 5775 Wayzata Boulevard, Minneapolis, MN 55416mincepmail@mincep.com
Submitted March 16, 2005 - Lower phenytoin serum levels in persons switched from brand to generic phenytoin
- Shanna A Stetz, Pharm.D., The Ohio State University Medical Center, Arthur G. James Cancer Hospital, Room 368 Doan Hall, 410 West 10th Ave, Columbus, OH 43210stetz-2@medctr.osu.edu
- Thomas Bechtel, Pharm.D.
Submitted March 16, 2005 - Lower phenytoin serum levels in persons switched from brand to generic phenytoin
- Russell J. Rackley, Executive Director, Pharmacokinetics and Drug Metabolism, Mylan Pharmaceuticals Inc., 3711 Collins Ferry Rd., Morgantown, WV 26505rrackley@mylanlabs.com
Submitted March 16, 2005 - Lower phenytoin serum levels in persons switched from brand to generic phenytoin
- James H. Sherry, Medical Director, Mylan Laboratories Inc., 781 Chestnut Ridge Road, P.O. Box 4310, Morgantown, WV 26504-4310jsherry@mylanlabs.com
Submitted March 15, 2005 - Lower phenytoin serum levels in persons switched from brand to generic phenytoin
- Richard J Jefferys, Treatment Action Group, 611 Broadway, Suite 608, New York, NY 10012richard.jefferys@verizon.net
Submitted March 15, 2005 - Reply to Wiberg
- Ilo E. Leppik, MD, MINCEP Epilepsy Care, 5775 Wayzata Blvd., Minneapolis, MN 55416kathy_pieper@urmc.rochester.edu
Submitted December 22, 2004 - Lower phenytoin serum levels in persons switched from brand to generic phenytoin
- Cody C. Wiberg, Minnesota Department of Human Services, 444 Lafayette Road St. Paul, MN 55155-3853cody.c.wiberg@state.mn.us
Submitted December 22, 2004 - Editors' Response
- Steven R. Schwid, MD, Department of Neurology-Neuroimmunology, 601 Elmwood Ave., Box 605, University of Rochester, Rochester, NY 14642steven_schwid@urmc.rochester.edu
- Robert A. Gross, MD, PhD; Jonathan W. Mink, MD, PhD, Robert C. Griggs, MD
Submitted December 22, 2004 - Reply to Perron
- Ilo Leppik, MD, MINCEP Epilepsy Care, 5775 Wayzata Blvd., Minneapolis, MN 55416kathy_pieper@urmc.rochester.edu
- James C. Cloyd III, PharmD
Submitted December 22, 2004 - Lower phenytoin serum levels in persons switched from brand to generic phenytoin
- Reed Perron, Neurology Group of Bergen County, PA, 1200 E Ridgewood Avenue, Ridgewood, NJ 07450rcperron@aol.com
Submitted December 22, 2004
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David Beversdorf and Dr. Ryan Townley
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Articles
Effect of food on absorption of Dilantin Kapseals and Mylan extended phenytoin sodium capsulesB. J. Wilder, I. Leppik, T. J. Hietpas et al.Neurology, August 28, 2001 -
Articles
Pharmacology and pharmacokinetics of fosphenytoinThomas R. Browne, Alan R. Kugler, Michael A. Eldon et al.Neurology, June 01, 1996 -
Articles
Generic substitution in the treatment of epilepsyCase evidence of breakthrough seizuresM. J. Berg, R. A. Gross, K. J. Tomaszewski et al.Neurology, August 11, 2008 -
Article
Assessing bioequivalence of generic modified-release antiepileptic drugsEmily L. Johnson, Yi-Ting Chang, Barbara Davit et al.Neurology, March 25, 2016